| Code | CSB-RA023984MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to CTX-471, designed to target TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in enhancing T cell proliferation, survival, and cytotoxic function. Upon engagement with its ligand 4-1BBL, TNFRSF9 delivers potent stimulatory signals that augment cellular immune responses. This pathway has emerged as a significant target in cancer immunotherapy research, as TNFRSF9 activation can enhance anti-tumor immunity and promote immune memory formation.
CTX-471 is an investigational agonistic antibody that selectively activates TNFRSF9 signaling in the tumor microenvironment while minimizing systemic immune activation. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF9-mediated immune regulation, exploring combination immunotherapy strategies, and studying T cell activation mechanisms in oncology and immunology research settings.
There are currently no reviews for this product.